Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CohBar Inc CWBR

Healthcare Biotechnology
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to... see more

Recent & Breaking News (GREY:CWBR)

CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

GlobeNewswire April 26, 2019

CohBar Announces Key Opinion Leader Conference Call and Webcast

GlobeNewswire April 23, 2019

CohBar Announces the Appointment of David Greenwood to its Board of Directors

GlobeNewswire April 22, 2019

CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire March 18, 2019

CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

GlobeNewswire February 11, 2019

CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer

GlobeNewswire December 10, 2018

Research Report Identifies Equinix, Universal Electronics, LHC Group, Cohbar, Amgen, and Aetna with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire November 29, 2018

CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

GlobeNewswire November 26, 2018

CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire November 14, 2018

CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine’s Health Care 50

GlobeNewswire November 8, 2018

CohBar Provides Update on CB4211 Clinical Trial

GlobeNewswire November 5, 2018

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

GlobeNewswire October 31, 2018

Recent Analysis Shows Renren, LiveXLive Media, Pivotal Software, Sun Life Financial, Gold Standard Ventures, and Cohbar Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire October 22, 2018

CohBar Engages LifeSci Advisors as Investor Relations Partner

GlobeNewswire September 25, 2018

CohBar Announces Second Quarter 2018 Financial Results

GlobeNewswire August 14, 2018

CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018

GlobeNewswire August 2, 2018

CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH

GlobeNewswire July 12, 2018

CohBar Completes Sale of $20 Million Under Controlled Equity Offering

GlobeNewswire June 27, 2018

CohBar Added to Russell 2000® Index

GlobeNewswire June 27, 2018

CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions 

GlobeNewswire June 25, 2018